Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

15
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
15
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.

Heliyon·2023
Same author

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

Blood cancer journal·2023
Same author

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy.

Frontiers of medicine·2023
Same author

Physicians' knowledge of invasive fungal disease in China.

Mycoses·2023
Same author

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients.

Experimental hematology & oncology·2023
Same author

Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia.

Clinical epigenetics·2023

Related Experiment Video

Updated: Feb 16, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

826

High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity.

Liangjing Xu1,2,3,4, Jinge Xu1,2,3,4,5, Shoubao Ma2,3,4

  • 1Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Oncotarget
|December 20, 2017
PubMed
Summary

High T-cell immunoglobulin and mucin domain-containing molecule3 (Tim-3) expression on acute myeloid leukemia (AML) blasts correlates with better prognosis and enhanced chemotherapy sensitivity. This finding suggests Tim-3 may be a therapeutic target in AML treatment.

Keywords:
Tim-3acute leukemiachemotherapyexpression

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

976
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.6K

Related Experiment Videos

Last Updated: Feb 16, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

826
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

976
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.6K

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • T-cell immunoglobulin and mucin domain-containing molecule3 (Tim-3) is implicated in T-cell exhaustion and identified in solid tumors.
  • The role of Tim-3 expression on blast cells in acute myeloid leukemia (AML) remains poorly understood.

Purpose of the Study:

  • To investigate the role of Tim-3 expression in de novo AML patients.
  • To explore the correlation between Tim-3 expression and clinicopathological prognosis in AML.

Main Methods:

  • Bone marrow samples from 76 de novo non-M3 AML patients were analyzed.
  • Flow cytometry was used to detect Tim-3 expression on blast cells.
  • Correlation with FAB type, genetic mutations, risk groups, and clinical outcomes was assessed.

Main Results:

  • Tim-3 expression was detected in 87% of AML patients, with an average blast expression of 58.26%.
  • High Tim-3 expression was associated with FAB M4 subtype, inv(16), C/EBPA mutation, and the low-risk group.
  • High Tim-3 expression correlated with higher complete remission rates and decreased post-remission expression, and enhanced chemotherapy sensitivity in vitro.

Conclusions:

  • High Tim-3 expression on AML blasts is linked to favorable prognostic factors and improved chemotherapy response.
  • Tim-3 expression decreases significantly after achieving complete remission.
  • Targeting Tim-3 may enhance chemotherapy sensitivity in AML patients.